Smith & Nephew plc SNN
30.32 USD -0.19 (-0.62%)
Regular-session close
30.30 -0.02 -0.05%
After hours · Nov 18, 5:05 PM ET
30.25 Day range 30.70
26.12 52-week range 37.09
- YTD
- -7.59%
- 1 year
- -6.82%
News
marketbeat.com Smith & Nephew SNATS Q3 Earnings Call Highlights Smith & Nephew SNATS NYSE: SNN lowered its full-year revenue and trading profit outlook after continued weakness in its U.S. knee and hip businesses tempered otherwise stronger third-quarter growth.
seekingalpha.com Smith & Nephew: Sluggish Growth And Shifting Outlook Now Make It Less Attractive (Rating Downgrade) Smith & Nephew faces credibility challenges after a profit warning and lowered guidance, despite recent share price gains. SNN cut the full-year underlying revenue growth forecast to 3% and halved…
seekingalpha.com Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcript Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcriptbenzinga.com Smith+Nephew Q3 Revenue Rises 3.4% YoY To $1.551B; $250M Of $500M Buyback Completed; Confirms Johnson & Johnson Talks Ended, Still Exploring Orthopaedics Strategic Options Smith+Nephew trading update for the quarter ended 26 September 2026.Q3 HighlightsQ3 revenue of $1,551 million (Q3 2025: $1,501 million), representing 3.4% revenue growth on both an underlying and…
zacks.com Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
globenewswire.com Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The…
globenewswire.com Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo. Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La…
globenewswire.com Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización…
zacks.com Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
defenseworld.net Smith & Nephew SNATS (NYSE:SNN) Reaches New 52-Week Low – Time to Sell? Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) shares reached a new 52-week low on Wednesday. The company traded as low as $27.05 and last traded at $27.0610, with a volume of 130820…
globenewswire.com MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company,…
globenewswire.com Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company,…
globenewswire.com Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International…
accessnewswire.com Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global…
accessnewswire.com Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global…
gurufocus.com Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued On September 14, 2026, Smith and Nephew PLC (SNN) shares rose 3.3% to a current price of $28.40. The stock has experienced a 52-week range between $27.23 and $37.
defenseworld.net Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low Following Analyst Downgrade Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) hit a new 52-week low on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The company traded as…
accessnewswire.com Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology…
proactiveinvestors.co.uk Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism Smith & Nephew PLC (LSE:SN) drew a cautious assessment from Jefferies on Friday, with the broker maintaining its 'buy' rating despite investor scepticism over execution and a reduced financial year…
proactiveinvestors.co.uk Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit Panmure Liberum has cut its target price for Smith & Nephew PLC (LSE:SN), the medical devices maker, to 1120p from 1250p, while maintaining its 'hold' rating. The broker said it still struggled to…
proactiveinvestors.co.uk UBS cuts Smith & Nephew target on competitive threats to three franchises UBS has cut its price target on Smith & Nephew PLC (LSE:SN) to 1,120p from 1,300p, warning that even the medical device group's recently reduced guidance for this year remains at risk. The neutral…
